A1 Refereed original research article in a scientific journal
In-Vivo Bone-Targeting of Bis(phosphonate)-Conjugated Double Helical RNA Monitored by Positron Emission Tomography
Authors: Satish Jadhav, Meeri Käkelä, Matthieu Bourgery, Kiira Rimpilä, Heidi Liljenbäck, Riikka Siitonen, Jussi Mäkilä, Tiina Laitala-Leinonen, Päivi Poijärvi-Virta, Harri Lönnberg, Anne Roivainen, Pasi Virta
Publisher: AMER CHEMICAL SOC
Publication year: 2016
Journal:Molecular Pharmaceutics
Journal name in sourceMOLECULAR PHARMACEUTICS
Journal acronym: MOL PHARMACEUT
Volume: 13
Issue: 7
First page : 2588
Last page: 2595
Number of pages: 8
ISSN: 1543-8384
DOI: https://doi.org/10.1021/acs.molpharmaceut.6b00261
Abstract
A bis(phosphonate) conjugate of 2'-O-methyl oligoribonucleotide (microRNA-21) was synthesized and used as a bone-targeting carrier in the systemic delivery of a Ga-68-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)chelated 2'-O-methyl oligoribonucleotide (anti-microRNA-21). The whole-body biodistribution of the double helical RNA was monitored by positron emission tomography (PET), which verified the expected bis(phosphonate)-induced bone accumulation in healthy rats.
A bis(phosphonate) conjugate of 2'-O-methyl oligoribonucleotide (microRNA-21) was synthesized and used as a bone-targeting carrier in the systemic delivery of a Ga-68-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)chelated 2'-O-methyl oligoribonucleotide (anti-microRNA-21). The whole-body biodistribution of the double helical RNA was monitored by positron emission tomography (PET), which verified the expected bis(phosphonate)-induced bone accumulation in healthy rats.
UTU Research Portal